Cemiplimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Melanoma · Phase 3

Also approved (5)
US
  • Adjuvant treatment of patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiationFDA label
  • LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation; for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. Basal Cell Carcinoma (BCC) for the treatment of adult patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. Non-Small Cell Lung Cancer (NSCLC) in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic; as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic.
    FDA label
Product first approved 2018Outside this platform's coverage
JP
  • Treatment of advanced or recurrent cervical cancer that has progressed after cancer chemotherapy
Product first approved 2022PMDA
EU
  • Cutaneous Squamous Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation (see section 5.1 for selection criteria). Basal Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell...
Product first approved 2019Outside this platform's coverageEMA
CA
  • Cutaneous Squamous Cell Carcinoma LIBTAYO (cemiplimab for injection) is indicated for: • the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. • the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation. Non-Small Cell Lung Cancer LIBTAYO (cemiplimab for injection) is indicated: • as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells...
Product first approved 2019Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Melanoma
NCT06246916 · Regeneron Pharmaceuticals
2024-09-09 – 2033-07-10 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07943325 · Goethe University
2027-02 – 2032-02 · Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT06931717 · ETOP IBCSG Partners Foundation
2026-01-12 – 2029-03 · Non-Small Cell Lung Cancer
What this study did
NCT06908304 · Maia Biotechnology
2025-12-08 – 2027-12-31 · Carcinoma, Non-Small -Cell Lung
What this study did
NCT03515629 · Regeneron Pharmaceuticals
2018-07-02 – 2021-07-29 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06568172 · National Cancer Institute (NCI)
2025-02-18 – 2031-08-14 · Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
What this study did
NCT06585410 · Regeneron Pharmaceuticals
2025-01-02 – 2030-05-03 · Cutaneous Squamous Cell Carcinoma (CSCC)
What this study did
NCT03969004 · Regeneron Pharmaceuticals
2019-06-04 – 2028-01-07 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT03257267 · Regeneron Pharmaceuticals
2017-09-05 – 2023-04-20 · Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
What this study did
Phase 2/3 (3)
Non-Small Cell Lung Cancer
NCT05800015 · Regeneron Pharmaceuticals
2023-08-08 – 2031-12-23 · Non-small Cell Lung Cancer
What this study did
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05785767 · Regeneron Pharmaceuticals
2023-06-30 – 2027-09-28 · Advanced Non-Small Cell Lung Cancer
What this study did
Phase 2 (107)
Melanoma
NCT06190951 · Regeneron Pharmaceuticals
2024-09-18 – 2030-12-09 · Melanoma
What this study did
NCT06121180 · H. Lee Moffitt Cancer Center and Research Institute
2024-11-04 – 2030-10-31 · Metastatic Uveal Melanoma
What this study did
NCT06848088 · Regeneron Pharmaceuticals
2025-04-14 – 2030-10-09 · Melanoma
What this study did
NCT07511036 · M.D. Anderson Cancer Center
2026-09-01 – 2030-05-24 · Melanoma
What this study did
NCT07527325 · University of California, Irvine
2026-12 – 2030-02-01 · Melanoma (Skin)
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT06594991 · Memorial Sloan Kettering Cancer Center
2024-09-10 – 2027-09 · Advanced Melanoma
What this study did
NCT04291105 · Vyriad, Inc.
2020-04-24 – 2026-12 · Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
What this study did
NCT04526899 · BioNTech SE
2021-05-19 – 2025-11-24 · Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07720167 · Medical University of South Carolina
2027-02-01 – 2036-08-01 · Non-Small Cell Lung Cancer
What this study did
NCT06465329 · Regeneron Pharmaceuticals
2024-11-18 – 2034-12-27 · Non Small Cell Lung Cancer, NSCLC
What this study did
NCT06918132 · Mayo Clinic
2025-05-02 – 2033-12-02 · Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06449313 · Georgetown University
2026-11 – 2032-09 · Non-small Cell Lung Cancer Stage III
What this study did
NCT07360743 · UNICANCER
2026-08-21 – 2032-04 · Non Small Cell Lung Cancer (Squamous or Non Squamous)
What this study did
NCT06623656 · Weill Medical College of Cornell University
2025-02-21 – 2032-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06656598 · Intergroupe Francophone de Cancerologie Thoracique
2025-11-07 – 2032-01 · Stage III NSCLC
What this study did
NCT06917573 · Fundación GECP
2025-07-29 – 2031-12-30 · Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Thoracic Neoplasms
What this study did
NCT07746388 · University of Maryland, Baltimore
2026-09-19 – 2031-09-01 · Nsclc, NSCLC Stage II, NSCLC, Stage III, NSCLC Stage IIIB, Resectable Lung Non-Small Cell Carcinoma
What this study did
NCT07418931 · Gruppo Oncologico Italiano di Ricerca Clinica
2026-05 – 2030-11 · Advanced Squamous Non-Small Cell Lung Cancer
What this study did
NCT07274384 · Università Vita-Salute San Raffaele
2026-01-01 – 2030-06-01 · NSCLC (Non-small Cell Lung Cancer), Hyperprogression
What this study did
NCT03916627 · Regeneron Pharmaceuticals
2019-07-23 – 2030-05-14 · Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06219317 · European Organisation for Research and Treatment of Cancer - EORTC
2025-01-14 – 2030-01 · NSCLC Stage IV
What this study did
NCT07808138 · The Netherlands Cancer Institute
2026-11 – 2029-12-01 · Non Small Cell Lung Cancer, Immunotherapy
What this study did
NCT05840770 · City of Hope Medical Center
2025-04-15 – 2029-10-30 · Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
What this study did
NCT06385262 · Duke University
2025-03-17 – 2029-10-30 · Non Small Cell Lung Cancer
What this study did
NCT07264673 · Fondazione Ricerca Traslazionale
2025-04-17 – 2029-10 · NSCLC
What this study did
NCT07946848 · Immuneering Corporation
2026-12 – 2029-07 · NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell Cancer, Locally Advanced Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
What this study did
NCT05557591 · Regeneron Pharmaceuticals
2023-04-21 – 2028-05-16 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06943664 · Roswell Park Cancer Institute
2026-08-15 – 2028-05-01 · Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT06731270 · Emory University
2025-04-09 – 2028-01-01 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT05208944 · Maia Biotechnology
2022-06-08 – 2027-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07450183 · Henry Ford Health System
2027-01-01 – 2027-12-01 · Lung Cancer (NSCLC)
What this study did
NCT04253964 · Wake Forest University Health Sciences
2020-07-01 – 2027-09-01 · Nonsmall Cell Lung Cancer, Performance Status
What this study did
NCT06865339 · Montefiore Medical Center
2025-08-07 – 2027-08 · NSCLC, Locally Advanced
What this study did
NCT05553834 · Duke University
2023-05-16 – 2026-11-01 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT05401786 · The Netherlands Cancer Institute
2023-01-03 – 2026-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04916002 · Regeneron Pharmaceuticals
2021-11-30 – 2024-10-31 · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
What this study did
Other / comorbidity
NCT07050186 · Northwestern University
2025-08-15 – 2035-11-20 · Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
What this study did
NCT07195734 · National Cancer Institute (NCI)
2026-04-24 – 2033-02-01 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT07620548 · Washington University School of Medicine
2026-11-30 – 2032-11-30 · Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
What this study did
NCT07470489 · M.D. Anderson Cancer Center
2026-10-29 – 2032-09-01 · Anaplastic Thyroid Cancer
What this study did
NCT07433673 · Columbia University
2027-01 – 2032-01 · Colon and Rectal Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07346196 · University of Chicago
2027-02-07 – 2031-08-22 · Squamous Cell Carcinoma
What this study did
NCT07387198 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2026-05-29 – 2031-07-31 · Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy
What this study did
NCT05929664 · Thomas Jefferson University
2023-07-05 – 2031-07-05 · Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT07715734 · Washington University School of Medicine
2026-11-30 – 2031-04-30 · Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
What this study did
NCT06769698 · Regeneron Pharmaceuticals
2026-04-14 – 2030-12-28 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
Phase 1/2 (36)
Melanoma
NCT06413680 · Regeneron Pharmaceuticals
2024-09-23 – 2030-02-03 · Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
What this study did
NCT04913220 · Sanofi
2021-07-15 – 2025-02-18 · Malignant Melanoma, Squamous Cell Carcinoma of Skin
What this study did
NCT03684785 · Exicure, Inc.
2018-12-13 – 2022-03-30 · Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
What this study did
Non-Small Cell Lung Cancer
NCT06088771 · Icahn School of Medicine at Mount Sinai
2024-10-09 – 2027-07-01 · Non-Small Cell Lung Cancer
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT06090266 · OncoResponse, Inc.
2023-10-24 – 2027-02-01 · Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
What this study did
NCT05882734 · EMD Serono Research & Development Institute, Inc.
2023-09-13 – 2026-07-15 · Non-Small Cell Lung Cancer
What this study did
NCT05864144 · Sensei Biotherapeutics, Inc.
2023-05-31 – 2026-06-02 · Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
What this study did
NCT05259696 · Palleon Pharmaceuticals, Inc.
2022-02-11 – 2024-10-24 · Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
What this study did
NCT05094804 · OncoResponse, Inc.
2021-09-09 – 2024-08-15 · Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
What this study did
NCT03367819 · Sanofi
2018-01-04 – 2021-03-10 · Prostate Cancer, Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07567469 · Regeneron Pharmaceuticals
2026-08-31 – 2034-08-17 · High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
What this study did
NCT07594106 · Regeneron Pharmaceuticals
2026-07-20 – 2030-10-27 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT06412198 · M.D. Anderson Cancer Center
2024-08-28 – 2029-03-01 · Metastatic Colorectal Cancer, KRAS G12C Mutations
What this study did
NCT07251413 · Instituto Oncológico Dr Rosell
2025-10-22 – 2028-12 · Cutaneous Basal Cell Carcinoma
What this study did
NCT04989946 · University of Wisconsin, Madison
2021-12-16 – 2028-12 · Prostate Cancer
What this study did
NCT04590326 · Regeneron Pharmaceuticals
2020-12-08 – 2028-11-08 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
What this study did
NCT06923761 · Grey Wolf Therapeutics
2023-05-21 – 2028-04-30 · Advanced Solid Malignancy
What this study did
NCT06384807 · Biohaven Therapeutics Ltd.
2024-04-22 – 2028-02 · Solid Tumor
What this study did
NCT03491683 · Inovio Pharmaceuticals
2018-05-31 – 2027-12-31 · Glioblastoma
What this study did
NCT03972657 · Regeneron Pharmaceuticals
2019-08-12 – 2027-11-15 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
What this study did
NCT04046107 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-01-01 – 2027-09-30 · Hepatitis B Virus
What this study did
NCT07147231 · National Cancer Institute (NCI)
2026-08-10 – 2027-09-30 · Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
What this study did
NCT04305795 · Rakuten Medical, Inc.
2020-12-21 – 2027-06 · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
What this study did
NCT03564340 · Regeneron Pharmaceuticals
2018-05-21 – 2027-05-10 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
What this study did
NCT04626635 · Regeneron Pharmaceuticals
2020-12-21 – 2027-03-05 · Advanced Solid Tumors
What this study did
NCT05662397 · HotSpot Therapeutics, Inc
2023-03-15 – 2026-12-31 · Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
What this study did
NCT05538988 · AHS Cancer Control Alberta
2024-12 – 2026-03 · Mycosis Fungoides
What this study did
NCT04706715 · University Medical Center Groningen
2022-01-18 – 2025-11 · Metastatic Solid Tumor
What this study did
NCT04339062 · Dana-Farber Cancer Institute
2020-11-03 – 2025-03-01 · Cutaneous Squamous Cell Carcinoma, Advanced Cancer
What this study did
NCT04382898 · BioNTech SE
2019-12-19 – 2024-01-23 · Prostate Cancer
What this study did
NCT03690869 · Regeneron Pharmaceuticals
2018-09-24 – 2023-05-10 · Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
What this study did
NCT03194867 · Sanofi
2018-02-21 – 2023-04-05 · Plasma Cell Myeloma
What this study did
NCT03294083 · SillaJen, Inc.
2018-06-19 – 2023-02-16 · Renal Cell Carcinoma
What this study did
NCT03769181 · Sanofi
2018-12-11 – 2022-11-08 · Lymphoma
What this study did
NCT03787095 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-08-13 – 2020-08-18 · HIV Infections
What this study did
Phase 1 (44)
Melanoma
NCT06022029 · OncoNano Medicine, Inc.
2023-10-13 – 2026-08-29 · Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
What this study did
Non-Small Cell Lung Cancer
NCT06171750 · Ankyra Therapeutics, Inc
2024-01-19 – 2027-06 · Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
What this study did
NCT04982224 · Regeneron Pharmaceuticals
2021-11-09 – 2025-10-15 · Advanced NSCLC
What this study did
NCT06052852 · Bolt Biotherapeutics, Inc.
2023-10-11 – 2025-08-01 · Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
What this study did
NCT03580694 · Regeneron Pharmaceuticals
2018-06-27 – 2019-12-04 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT07365839 · Virginia Commonwealth University
2026-10-01 – 2035-05-28 · Hepatocellular Carcinoma
What this study did
NCT03017820 · Mayo Clinic
2017-04-04 – 2032-04-01 · B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
What this study did
NCT06508463 · Mayo Clinic
2024-01-05 – 2032-04-01 · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
What this study did
NCT04428671 · Emory University
2020-05-15 – 2031-10-01 · Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
What this study did
NCT07404332 · Mohammed Milhem
2026-02-11 – 2031-02-28 · Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
What this study did
NCT07650266 · Memorial Sloan Kettering Cancer Center
2026-12 – 2030-07 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
What this study did
NCT06469281 · Regeneron Pharmaceuticals
2024-08-06 – 2030-05-27 · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
What this study did
NCT07869823 · Vanderbilt-Ingram Cancer Center
2026-09 – 2029-09 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT06826768 · M.D. Anderson Cancer Center
2025-07-09 – 2029-05-01 · Prostate Cancer
What this study did
NCT06874335 · Biohaven Therapeutics Ltd.
2025-03-20 – 2029-03 · Solid Tumor
What this study did
NCT06902376 · UNC Lineberger Comprehensive Cancer Center
2025-06-03 – 2028-08-31 · Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
What this study did
NCT05729139 · Baptist Health South Florida
2023-07 – 2028-07 · Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT04975152 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-22 – 2028-03 · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
What this study did
NCT03233139 · Regeneron Pharmaceuticals
2017-06-21 – 2027-09-30 · Advanced Malignancies
What this study did
NCT04722523 · Memorial Sloan Kettering Cancer Center
2021-01-20 – 2027-06-20 · Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
What this study did
NCT05259709 · Regeneron Pharmaceuticals
2023-02-07 – 2027-04-29 · Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT07422363 · National Cancer Institute (NCI)
2026-12-04 – 2027-02-28 · Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
What this study did
NCT06302426 · Inimmune Corporation
2024-07-01 – 2026-06-19 · Advanced Solid Tumor
What this study did
NCT02651662 · Regeneron Pharmaceuticals
2016-01-11 – 2026-04-29 · Relapsed/Refractory Aggressive B-Cell Lymphoma
What this study did
NCT03889912 · Regeneron Pharmaceuticals
2019-04-11 – 2025-12-10 · Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT05376553 · Krzysztof Misiukiewicz
2022-07-20 – 2025-10 · Locally Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT05064085 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-12 – 2025-03-13 · Hormone Receptor-positive Breast Cancer
What this study did
NCT04465487 · Regeneron Pharmaceuticals
2020-10-05 – 2025-02-07 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT05054348 · Immune-Onc Therapeutics
2021-09-30 – 2024-05-31 · Solid Tumor, Adult
What this study did
NCT03005782 · Regeneron Pharmaceuticals
2016-11-07 – 2024-04-02 · Malignancies
What this study did
NCT04826393 · Dana-Farber Cancer Institute
2022-03-09 – 2024-01-01 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT02520245 · Regeneron Pharmaceuticals
2015-08 – 2023-11 · Advanced Malignancies
What this study did
NCT04729725 · M.D. Anderson Cancer Center
2021-02-09 – 2022-12-02 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT04460456 · Silverback Therapeutics
2020-07-27 – 2022-12 · HER2 Positive Solid Tumors
What this study did
NCT03198130 · Regeneron Pharmaceuticals
2017-07-03 – 2020-02-21 · Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head, Metastatic Squamous Cell Carcinoma Neck
What this study did
NCT02383212 · Regeneron Pharmaceuticals
2015-02-02 – 2019-11-18 · Advanced Cancer, Advanced Malignancies
What this study did
NCT03477864 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2018-12-24 – 2019-11-04 · Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT06743581 · Centre hospitalier de l'Université de Montréal (CHUM)
2025-08-19 – 2030-02 · Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
Phase 2 (6)
Non-Small Cell Lung Cancer
NCT07020065 · Swiss Cancer Institute
2026-04-10 – 2030-09 · Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
Other / comorbidity
NCT07223541 · University of Oklahoma
2026-01-15 – 2031-08 · Clear Cell Renal Cell Carcinoma
What this study did
NCT04050436 · Replimune, Inc.
2019-10-08 – 2025-09 · Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
What this study did
NCT03669718 · ISA Pharmaceuticals
2018-11-30 – 2025-06 · Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT06162572 · Servier Bio-Innovation LLC
2024-08-07 – 2027-07 · Non-small Cell Lung Cancer (NSCLC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cemiplimab: this drugApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RelatlimabPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 97 furthest-along competitors are listed; 516 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(119 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cemiplimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Phase 2Prostate Cancer MetastaticActive not recruiting
Est. primary completion 2026-11 · NCT03951831 · CT.gov ↗
What to watch
December 2026 (4)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT04989946 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06623656 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer …Active not recruiting
Est. primary completion 2026-12-31 · NCT04315701 · CT.gov ↗
What to watch
2027 (35)
January 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-01-15 · NCT05608291 · CT.gov ↗
What to watch
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the LiverRecruiting
Est. primary completion 2027-01-30 · NCT06860815 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 GliomaNot yet recruiting
Est. primary completion 2027-02-28 · NCT07422363 · CT.gov ↗
What to watch
March 2027 (2)
Phase 3MelanomaRecruiting
Est. primary completion 2027-03-22 · NCT06246916 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT06171750 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Metastatic Solid TumorActive not recruiting
Est. primary completion 2027-04-29 · NCT05259709 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid MalignancyActive not recruiting
Est. primary completion 2027-04-30 · NCT06923761 · CT.gov ↗
What to watch
Phase 2Colon CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT05961709 · CT.gov ↗
What to watch
May 2027 (3)
Phase 1Prostate CancerRecruiting
Est. primary completion 2027-05-01 · NCT06826768 · CT.gov ↗
What to watch
Phase 1/2Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer …Recruiting
Est. primary completion 2027-05-10 · NCT03564340 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Oral Cavity Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-15 · NCT06448026 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCCRecruiting
Est. primary completion 2027-06-20 · NCT04722523 · CT.gov ↗
What to watch
Phase 2HPV-Related Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT04988074 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary CarcinomaRecruiting
Est. primary completion 2027-07-31 · NCT06444880 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-31 · NCT06908304 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06865339 · CT.gov ↗
What to watch
September 2027 (6)
Phase 2MelanomaRecruiting
Est. primary completion 2027-09 · NCT06594991 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-28 · NCT05785767 · CT.gov ↗
What to watch
Phase 1Advanced MalignanciesActive not recruiting
Est. primary completion 2027-09-30 · NCT03233139 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 …Recruiting
Est. primary completion 2027-09-30 · NCT07147231 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT05208944 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10 · NCT07264673 · CT.gov ↗
What to watch
Phase 2Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-10-06 · NCT05574101 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2027-11-15 · NCT03972657 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-11-24 · NCT06980038 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06449313 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07450183 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03491683 · CT.gov ↗
What to watch
Phase 2Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck …Active not recruiting
Est. primary completion 2027-12-31 · NCT03565783 · CT.gov ↗
What to watch
Phase 2Leiomyosarcoma, SarcomaRecruiting
Est. primary completion 2027-12-31 · NCT06528769 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
2028 (33)
January 2028 (4)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT05704634 · CT.gov ↗
What to watch
Phase 3Cutaneous Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-07 · NCT03969004 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-26 · NCT05557591 · CT.gov ↗
What to watch
February 2028 (3)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2028-02 · NCT06384807 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-02 · NCT06699602 · CT.gov ↗
What to watch
Phase 1Solid Tumor, Locally Advanced Solid Tumor, Metastatic TumorRecruiting
Est. primary completion 2028-02-28 · NCT07404332 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1Merkel Cell Carcinoma, Cutaneous Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03 · NCT04975152 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT06855212 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 1Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related TumorsRecruiting
Est. primary completion 2028-03-31 · NCT06902376 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma …Active not recruiting
Est. primary completion 2028-04-07 · NCT05694871 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-05 · NCT07418931 · CT.gov ↗
What to watch
Phase 2Pleural MesotheliomasRecruiting
Est. primary completion 2028-05 · NCT07234058 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-05-24 · NCT07511036 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Pancreatic Cancer, Adenocarcinoma of the Pancreas, AdenocarcinomaActive not recruiting
Est. primary completion 2028-06 · NCT04543071 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)Recruiting
Est. primary completion 2028-06-04 · NCT06769698 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruiting
Est. primary completion 2028-06-30 · NCT06787612 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Adrenal Cortical CarcinomaRecruiting
Est. primary completion 2028-07 · NCT07085572 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (mPDAC)Recruiting
Est. primary completion 2028-07 · NCT06790602 · CT.gov ↗
What to watch
September 2028 (3)
Phase 1Cutaneous Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-09 · NCT07869823 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06656598 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-09-01 · NCT06651593 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Basal Cell Carcinoma (BCC), First Line TreatmentRecruiting
Est. primary completion 2028-10 · NCT06981325 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-30 · NCT06385262 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1/2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial CancerRecruiting
Est. primary completion 2028-11-08 · NCT04590326 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (6)
Phase 1/2Cutaneous Basal Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07251413 · CT.gov ↗
What to watch
Phase 2Vulvar CancersNot yet recruiting
Est. primary completion 2028-12 · NCT07101848 · CT.gov ↗
What to watch
Phase 2Penile CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07101822 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07360743 · CT.gov ↗
What to watch
Phase 1B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-12-31 · NCT03017820 · CT.gov ↗
What to watch
Phase 1Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified …Recruiting
Est. primary completion 2028-12-31 · NCT06508463 · CT.gov ↗
What to watch
2029 (15)
February 2029 (1)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07527325 · CT.gov ↗
What to watch
March 2029 (3)
Phase 1Solid TumorRecruiting
Est. primary completion 2029-03 · NCT06874335 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03 · NCT06931717 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, KRAS G12C MutationsRecruiting
Est. primary completion 2029-03-01 · NCT06412198 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Colo-rectal CancerRecruiting
Est. primary completion 2029-04-17 · NCT07058012 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin CancerActive not recruiting
Est. primary completion 2029-05 · NCT05878288 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07946848 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma …Recruiting
Est. primary completion 2029-06-02 · NCT06900595 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2Head and Neck CancerRecruiting
Est. primary completion 2029-11-30 · NCT07179315 · CT.gov ↗
What to watch
Phase 2Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2029-11-30 · NCT07188896 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07808138 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-12-04 · NCT06465329 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07274384 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07224022 · CT.gov ↗
What to watch
Phase 2Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant ImmunotherapyRecruiting
Est. primary completion 2029-12-31 · NCT07387198 · CT.gov ↗
What to watch
2030 (22)
January 2030 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01 · NCT06219317 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗
What to watch
February 2030 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-02 · NCT05142189 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-02-03 · NCT06413680 · CT.gov ↗
What to watch
May 2030 (3)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-05 · NCT06205836 · CT.gov ↗
What to watch
Phase 3Cutaneous Squamous Cell Carcinoma (CSCC)Recruiting
Est. primary completion 2030-05-03 · NCT06585410 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube CancerRecruiting
Est. primary completion 2030-05-27 · NCT06469281 · CT.gov ↗
What to watch
July 2030 (3)
Phase 1Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx CancerNot yet recruiting
Est. primary completion 2030-07 · NCT07650266 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-07 · NCT07281768 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-07-30 · NCT06418724 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09 · NCT07001618 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09-01 · NCT07746388 · CT.gov ↗
What to watch
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2030-09-01 · NCT07470489 · CT.gov ↗
What to watch
October 2030 (4)
Phase 1Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2030-10-01 · NCT04428671 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2030-10-09 · NCT06848088 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)Recruiting
Est. primary completion 2030-10-27 · NCT07594106 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2030-10-31 · NCT06121180 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Locally Advanced Basal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-11-13 · NCT07808515 · CT.gov ↗
What to watch
Phase 2Metastatic NUT Carcinoma, Unresectable NUT CarcinomaRecruiting
Est. primary completion 2030-11-20 · NCT07050186 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-12-02 · NCT06918132 · CT.gov ↗
What to watch
Phase 2Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8 …Recruiting
Est. primary completion 2030-12-16 · NCT07281417 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 2Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney TransplantNot yet recruiting
Est. primary completion 2031-04-30 · NCT07715734 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeNot yet recruiting
Est. primary completion 2031-05-31 · NCT07620548 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07346196 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-12-30 · NCT06917573 · CT.gov ↗
What to watch
2032 (3)
January 2032 (1)
Phase 2Colon and Rectal CancerRecruiting
Est. primary completion 2032-01 · NCT07433673 · CT.gov ↗
What to watch
February 2032 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-02 · NCT07943325 · CT.gov ↗
What to watch
August 2032 (1)
Phase 1/2High-Grade Glioma (HGG), Posterior Fossa-A EpendymomaNot yet recruiting
Est. primary completion 2032-08-27 · NCT07567469 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 2Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Recruiting
Est. primary completion 2033-02-01 · NCT07195734 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2035-08-01 · NCT07720167 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

March 2027FDA action dateFDA decision on the Libtayo alternative-dosing sBLA expected March 2027
US, FDA · Source ↗

Recent

17 November 2026ApprovalEuropean Commission approves an extended Libtayo dosing schedule (700 mg every six weeks) and shorter infusion
EU, European Commission · Source ↗
17 May 2026Topline resultPhase 3 of fianlimab plus cemiplimab vs pembrolizumab in first-line melanoma (NCT05352672) missed its PFS primary endpoint